Business
Exclusive distribution agreement with DKSH Japan
Exclusive distribution agreement with DKSH Japan.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 7784D Avacta Group PLC 29 March 2011 \n \n\n \n\n \n\n\n\n\nPress release \n\n\n29 March 2011\n\n\n\n\n \nAvacta Group plc\n(\"Avacta\" or \"the Company\")\n \nAvacta Analytical signs exclusive distribution agreement with DKSH Japan\n \nOptim enters substantial Japanese market with its first order\n \nAvacta Group plc (AIM:AVCT), the provider of innovative, high value proprietary technologies and services to the pharmaceutical and diagnostics markets is pleased to announce that it has signed an exclusive agreement for the distribution of Optim, the market leading low volume protein analysis system, with DKSH Japan (\"DKSH\"), the leading Market Expansion Services Group with a focus on Asia. \n \nDKSH, the £5.8bn turnover group specialising in Asian markets business development, has nearly 50 years experience in supporting the Japanese pharmaceutical industry through its dedicated Business Unit Technology which has a specialised sales team of seven. It has strong contacts within the rapidly growing biopharmaceutical industry and with the large and expanding life sciences research base in Japan. \n \nJapan is the second largest biotechnology market after the USA with over 500 bioventures, and is expected to grow ten times in volume by 2017 along with the rest of the worldwide market for protein therapeutics. Avacta has already received its first order for an Optim unit which will be shipped to DKSH in April.\n \nOptim, which comprises a benchtop instrument and disposable sample holders, accelerates the speed, reduces the cost, and reduces the risk of failure, early on in the biopharmaceutical development process. \n \nAt the critical stages of pre-formulation, stability testing and formulation of biopharmaceutical drugs the Optim system provides analysis of compounds to identify viable drug candidates and to define the optimal processing conditions. \n \nOptim not only delivers information tens of times faster than existing techniques, using less than a hundredth of the sample size, the quality of the data gives drug developers a greater insight into candidate drugs much earlier in their development.\n \nThis quantum leap in efficiency leads to a significant reduction in the likelihood of failure of drug compounds and reduces the overal...